knowledge -WSS

knowledge

author：Wikipedia 2025-09-27 23:51:45 - browse：23298

The Amgen booth at ESMO in Madrid. Andrew Joseph/STAT

MADRID — A novel type of immunotherapy from Amgen generated strong response rates in patients with advanced small cell lung cancer, results that could lead to the approval of the drug.

The data, reported here Friday at the annual meeting of European Society for Medical Oncology, come from a Phase 2 trial of the drug, called tarlatamab. But they drew greater interest because Amgen has described the study as “potentially registrational,” and the trial results were also published Friday in the New England Journal of Medicine.

“It’s a single arm study, but the results are amazing,” said Silke Gillessen, the scientific chair of ESMO 2023 and an oncologist at the Oncology Institute of Southern Switzerland, noting that advances in small cell lung cancer have been slow to come.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Solve the antibiotic resistance crisis with preventive drugs

focus

Wikipedia

WSS

Medicare reduced heart disease by changing how it pays doctors

Beam Therapeutics to lay off 20% of its staff, re

FDA warns J&J's Abiomed: We will regulate your software

Solve the antibiotic resistance crisis with preventive drugs

Lawmakers consider Medicare pay reforms for doctors

Ahead of JPM, here's who's profiting most in health care

hotspot

knowledge

Wikipedia

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

J&J to buy cancer drug developer Ambrx Biopharma

Activists slam private health insurers over coverage restrictions

How climate

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

3 trends to watch in health tech's hiring outlook for 2024

Wildfire smoke exposes gaps in outdoor worker protections

Studies point to risks of excluding people with obesity from drug trials

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Videos point to link between seizures and unexplained toddler deaths

entertainment

Solve the antibiotic resistance crisis with preventive drugs

Readout Newsletter: Allogene's pivot, Illumina exec to lead Delfi

The EU Joint Clinical Assessment needs to live up to its promise

FDA warns J&J's Abiomed: We will regulate your software

FDA warns J&J's Abiomed: We will regulate your software

Senate committee scrutinizes Medicare Advantage brokers

focus

Wikipedia

focus

explore